News & Media

CardioCel: 8 years on and still free from calcification

23, August, 2016

Posted In: Featured, Blog, Uncategorized

CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]

> Read more

Long-term CardioCel study shows no evidence of calcification after 8 years

22, August, 2016

Posted In: Uncategorized

Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.

> Read more

Long-term study indicates no calcification with CardioCel after eight years

22, August, 2016

Posted In: In the media, Uncategorized

Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.

> Read more

Admedus Investor Presentation – July 2016

26, July, 2016

Posted In: Videos, Uncategorized

> Watch the video

Using the ADAPT engineering process to create durable tissue scaffolds

8, July, 2016

Posted In: Featured, Blog, Uncategorized

Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]

> Read more

Admedus a major distributor of infusion solutions

10, June, 2016

Posted In: Blog, Uncategorized

Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]

> Read more

Admedus shares rise on hospital infusion pump supply deal with Arcomed

25, May, 2016

Posted In: Featured, In the media, Uncategorized

Admedus said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems. The supply tender includes ongoing technical and clinical support as well as consumable products for the systems over the next 5 years.

> Read more

Admedus Wins 2016 Australian Manufacturer of the Year Award

14, May, 2016

Posted In: Featured, In the media, Uncategorized

After triumphing in the Most Innovative category, Admedus also took out the night’s biggest award ‘Manufacturer of the Year’. In August 2014 Admedus opened its state-of-the-art bio-manufacturing facility in Malaga, WA, and has experienced huge success in exporting its bio-scaffold regenerative medicine product, CardioCel, since then.

> Read more

Admedus Investor Presentation – May 2016

5, May, 2016

Posted In: Videos, Uncategorized

> Watch the video

A day with Europe’s leading cardiovascular surgeons

5, May, 2016

Posted In: Blog, Uncategorized

In April, I had the privilege of spending the day with over forty of Europe’s leading cardiovascular surgeons. The purpose – an Admedus workshop to discuss the use of CardioCel to reconstruct heart valves and its potential in the future treatment of heart valve disease. Held in Amsterdam, the experts meeting shed light on the critical issues and […]

> Read more